Mitralign Gets $35 Million For Less Invasive Mitral Regurgitation Treatment

As we continue to track the new technologies impacting heart valve treatment, I thought you might like to know about an interesting treatment method for mitral regurgitation. The Mitralign device enables physicians to repair a mitral valve using a catheter-based procedure instead of an incision to the sternum or ribs.

Logo Of Mitralign Company

Unlike the Mitraclip, another transcatheter technology which clips the mitral valve leaflets together to reduce regurgitation, the Mitralign system repairs a dilated mitral valve by reducing the size of the annulus which moves the leaflets closer together. The result is a decrease in mitral insufficiency.

Mitralign is currently conducting clinical studies. Ultimately, its recent $35 million financing, will be used to secure a European CE Mark that will enable Mitralign to market the device overseas. As you may be aware, this approach is common for companies with new technologies that eventually apply for FDA approval here in the United States.

As we continue to learn more about this and other exciting technologies, I’ll continue to feature them here in this blog.

Keep on tickin!

Adam Pick
Written by Adam Pick

Adam Pick is a patient, author of The Patient's Guide To Heart Valve Surgery and the founder of HeartValveSurgery.com.

To learn how Adam has helped millions of people with heart valve disease, watch Adam's video, subscribe to his free newsletter, or visit his Facebook, or Twitter pages.

Have A Question? Call Us at (888) 725-4311

HeartValveSurgery.com
P.O. Box 4049
Redondo Beach, CA 90277
Phone: (888) 725-4311